| abstract |
Method of identifying compounds that modulate intermolecular interactions between a target protein, such as β- lactamase, and a modifier, e.g. a substrate, are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between the target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed. nThe drug screening method is based on the identification of an allosteric-like cavity near (15-20 Å), but distinct from the critically active (catalytic) site, which interacts with the modifier. |